The FDA has granted final approval to Eagle Pharmaceuticals’ (EGRX -0.4%) Pemfexy (pemetrexed for injection), its branded alternative to Eli Lilly’s (LLY -2.2%) Alimta.
The agency granted tentative approval in October 2017 pending the resolution of patent issues.
https://seekingalpha.com/news/3540074-eagle-pharma-nabs-final-fda-nod-for-pemfexy
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.